Oncology Institute, Inc.

The Oncology Institute secured a new $75 million term loan facility from OrbiMed, maturing in 2031, to refinance its existing debt. The proceeds, along with $11 million cash on hand, were used to repay the outstanding $86 million 4% senior secured convertible notes due 2027 held by Deerfield Partners. As part of the repayment, the company issued warrants to Deerfield for 10,025,535 shares at an exercise price of $8.567. This strategic refinancing aims to strengthen the balance sheet, improve liquidity, and extend debt maturities without diluting existing shareholders.

The Oncology Institute, Inc. announced it has repaid its $86 million senior secured convertible note with Deerfield Partners through a debt refinancing. This transaction includes new credit facilities from OrbiMed, featuring a new $75 million term loan maturing in 2031. The company also utilized approximately $11 million in cash from its balance sheet to complete the repayment, aiming to increase liquidity, improve operating flexibility, and extend debt maturities without diluting existing shareholders.

The Oncology Institute, Inc. announced that its Chief Medical Officer, Dr. Yale D. Podnos, will participate in a panel discussion at the APG Spring Conference on May 28, 2026. The session, titled "Engaging More Specialists in Value-Based Care," will focus on the critical role of specialists in delivering high-quality, coordinated care, improving outcomes, and reducing costs within value-based models. Dr. Podnos will share insights on oncology's contribution to advancing value-based care delivery.

The Oncology Institute, Inc. disclosed a follow-up to a cybersecurity incident involving a third-party software service provider. On May 20, 2026, the company was notified that unauthorized access to its information systems, including patient data, was detected. Despite the incident, the company states its operations have continued in all material respects due to its security plan. The Oncology Institute will offer credit monitoring to impacted patients and believes the incident has not materially impacted its operations, financial systems, or quality of care, though it is still evaluating other potential impacts.

The Oncology Institute, Inc. announced that its CEO, Dr. Daniel Virnich, and CFO, Rob Carter, will attend the B. Riley Securities Institutional Investor Conference on May 21, 2026. They are scheduled to participate in a fireside chat from 9:00–9:40 a.m. PT. A webcast of the presentation will be available on the company's investor relations website.

The Oncology Institute, Inc. reported a significant improvement in its first-quarter 2026 financial results, with net loss narrowing to $(2.49) million from $(19.59) million in the prior year. Total operating revenue increased by 41.2% to $147.44 million, primarily driven by a substantial 77.6% growth in Specialty Pharmacy revenue. Despite an accumulated deficit, the company believes it has sufficient liquidity for the next year, while still facing vendor concentration risks.

The Oncology Institute, Inc. (TOI) will hold its Annual Meeting of Stockholders virtually on June 17, 2026. Stockholders will vote on the election of eight director nominees, the ratification of BDO USA, P.C. as the independent auditor for 2026, and two non-binding advisory votes on executive compensation. The Board recommends voting "FOR" all proposals and "ONE YEAR" for the frequency of future Say-on-Frequency votes.

The Oncology Institute, Inc. (TOI) announced it will release its first quarter 2026 financial results on Thursday, May 7, 2026. Following the release, the company will host a conference call on the same day at 5:30 p.m. Eastern Time to discuss the results. Investors can access the live call via phone or a simultaneous webcast on the company's investor relations website, with a replay available until May 21, 2026.